Yang G, Zhang B, Zha X-M, Wang N-N, Xing C-Y
Department of Nephrology, First Affiliated Hospital of Nanjing Medical University, 300# Guangzhou Road, Nanjing, Jiangsu, 210029, China.
Osteoporos Int. 2014 Mar;25(3):1115-21. doi: 10.1007/s00198-013-2488-1. Epub 2013 Aug 29.
We described six uremic leontiasis ossea (ULO) patients who underwent total parathyroidectomy with autotransplantation. ULO demonstrated more a systemic disease than a simple craniofacial deformation. The surgery seemed an effective treatment to alleviate secondary hyperparathyroidism and to improve patients' quality of life. ULO may have a high postoperative recurrence tendency.
ULO is a rare disease derived from uremic secondary hyperparathyroidism (SHPT). Previous studies mostly focused on the craniofacial deformations. This study aims to investigate the systemic features of the disease and the surgical outcomes.
The present study retrospectively assessed six ULO patients who underwent total parathyroidectomy (TPTX) with autotransplantation (AT). Follow-up data were recorded. The follow-up status was considered as "effectiveness" if serum intact parathyroid hormone (iPTH) levels were <150 pg/mL in the first 3 days after surgery, or as "recurrence" if serum iPTH gradually increased >300 pg/mL during follow-up in patients whose status was initially considered as "effectiveness".
Craniofacial deformations, short stature, thoracocyllosis, spine malformations, osteodynia, and muscle weakness were observed in all patients. Abnormal pulmonary functions were observed in five patients. After surgery, one patient died from respiratory failure. Surgery was effective in the remaining five patients with relieved osteodynia and stopped craniofacial deformation. A mean follow-up of 7.6 (4 to 12) months was available. Three patients suffered from recurrence of hyperparathyroidism originating from autografts.
Our data suggests that ULO is not only a simple disease with craniofacial malformations but is a severe systemic disease leading to increased surgical risks. TPTX with AT seems an effective treatment to relieve SHPT and to improve quality of life. ULO may have a high postoperative recurrence tendency.
我们描述了6例接受甲状旁腺全切除术并自体移植的尿毒症性骨肥大(ULO)患者。ULO表现为一种全身性疾病,而非单纯的颅面畸形。手术似乎是缓解继发性甲状旁腺功能亢进和改善患者生活质量的有效治疗方法。ULO可能具有较高的术后复发倾向。
ULO是一种源于尿毒症继发性甲状旁腺功能亢进(SHPT)的罕见疾病。既往研究大多聚焦于颅面畸形。本研究旨在探讨该疾病的全身特征及手术效果。
本研究回顾性评估了6例接受甲状旁腺全切除术(TPTX)并自体移植(AT)的ULO患者。记录随访数据。若术后第1天血清完整甲状旁腺激素(iPTH)水平<150 pg/mL,则随访状态视为“有效”;若最初状态被视为“有效”的患者在随访期间血清iPTH逐渐升高>300 pg/mL,则视为“复发”。
所有患者均观察到颅面畸形、身材矮小、胸廓畸形、脊柱畸形、骨痛和肌无力。5例患者存在肺功能异常。术后,1例患者死于呼吸衰竭。手术对其余5例患者有效,骨痛缓解,颅面畸形停止发展。平均随访时间为7.6(4至12)个月。3例患者发生自体移植引起的甲状旁腺功能亢进复发。
我们的数据表明,ULO不仅是一种伴有颅面畸形的简单疾病,而且是一种导致手术风险增加的严重全身性疾病。TPTX联合AT似乎是缓解SHPT和改善生活质量的有效治疗方法。ULO可能具有较高的术后复发倾向。